IHIBITION OF TRNA QUEUOSINE MODIFICATION CAUSE MITOCHONDRIAL DYSFUNCTION AND APOPTOSIS IN THE INTESTINAL EPITHELIAL CELLS

Abstract

Abstract BACKGROUND Transfer RNA (tRNA) modifications occur through the action of specific enzymes that recognize and modify the nucleotides within the tRNA molecule. Queuine tRNA-ribosyltransferase catalytic subunit 1 (QTRT1) and QTRT 2 co-localize in mitochondria and form a heterodimeric TGT participating in tRNA Queuosine (tRNA-Q) modification. Our previous study demonstrated that Q-tRNA modification plays a novel role in regulating barrier functions of intestinal epithelial cells. However, the roles of tRNA-Q modifications in the maintenance of intestinal mitochondrial homeostasis and the progression of inflammatory bowel disease (IBD) are still unclear. METHODS We used QTRT1 knockout (KO) mice and cultured cell lines with QTRT1 knockdown (KD) to investigate the impact and mechanism of tRNA-Q modifications in intestinal mitochondrial homeostasis and inflammation. RESULTS Initially, we confirmed QTRT1's mitochondrial localization through immunofluorescence co-localization with Mitotracker staining in QTRT1 KD CaCO2-BBE cells. Then we used flow cytometry MitoSox Red staining and revealed an increase in mitochondrial ROS production in QTRT1 KD cells. Furthermore, we observed heightened mitophagy both in vitro and in the colon of QTRT1KO mice, evident through significantly enhanced fusion of Mtphagy Dye-labeled mitochondria with lysosomes, and altered mitochondrial proteins (Tomm20, LC3, and Cytochrome C) via Western Blotting. Notably, we identified an increase in apoptosis in the QTRT1 KO mice evidenced by the upregulation of phosphorylated PARP, cleaved Caspase 3, and the Bax/BCL-2 ratio in colonic mitochondrial proteins. TUNEL staining corroborated this apoptosis increase specifically in the colon due to the QTRT1 deficiency. CONCLUSIONS Reduced QTRT1 induced dysfunctional mitochondria and Caspase-3 dependent apoptosis. tRNA-Q modification plays an unexplored role in the pathogenesis of mitochondrial function in the intestine. Our upcoming research will employ N-acetyl-l-cysteine, a mitochondrial ROS inhibitor, and a Caspase 3 specific inhibitor to ascertain the role of tRNA modification in mitochondrial function in the intestinal inflammation. Insights into tRNA-Q modification will pave the road for new therapeutic strategies to restore mitochondrial function in IBD.